Kopran Limited (KOPRAN) · mywealthgrid

Loading page…

About

Kopran operates in Indian pharmaceuticals at ₹918.67 Cr market cap. Quarterly revenues range ₹42–₹234 Cr (standalone). Stock returned 19.97% past year despite Sep 2025 losses; recent recovery suggests operational stabilization.

Face value: ₹10

Market cap

₹1,362 Cr

P/E

54.5×

P/B

2.6×

Dividend yield

2.1%

ROE

4.9%

ROCE

7.8%

Debt / equity

0.29

OPM

9.1%

EPS (TTM)

₹5.2

Book value

₹109.8

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Profitability volatile: swung from -₹9.92 Cr (Sep 2025) to +₹18.87 Cr (Mar 2026); sustainability unclear
Operating margins unstable: -7.55% (Sep 2025) to 22.52% (Mar 2026), averaging 9.09%. Verify if Sep losses were one-time or structural
ROE of 4.91% is weak for pharma, indicating poor capital efficiency
PE of 36.76 leaves no buffer for earnings misses or multiple compression

Generated analysis · source review pending

Growth drivers

Operating margin recovered from -4.48% (Sep 2025 consolidated) to 10.25% (Jun 2026 consolidated), indicating operational issues addressed
Net profit recovered from -₹9.92 Cr loss (Sep 2025 consolidated) to +₹6.7 Cr (Jun 2026 consolidated), though below Mar 2026 peaks
Dividend payments continue (latest Aug 2026), indicates management confidence in cash generation despite volatility
Debt-to-equity of 0.29 provides financial flexibility for growth or downside navigation

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹282.1-3%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of 4.2% (3-yr avg)
−Profit declined 16% a year over the last 5 years
−Modest revenue growth of 6.7% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

28/100

Business quality: 26
Growth: 23
Valuation: 35

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	319	315	358	360	492	478	551	615	630	681
COGS	181	188	208	210	302	271	359	402	405	439
Gross profit	138	127	150	149	190	206	192	213	225	242
	102	96	104	103	108	119	141	138	152	180
	36	30	46	47	82	87	52	74	73	62
OPM %	11.3%	9.7%	12.9%	13%	16.6%	18.3%	9.4%	12.1%	11.6%	9.1%
Depreciation	8	9	9	10	10	11	13	13	16	17
Interest	14	9	9	9	6	5	6	9	9	10
	11	10	3	0	18	11	3	15	4	0
Profit before tax	25	23	32	28	83	82	36	68	52	34
Tax	5	2	8	7	22	21	9	17	13	9
Tax %	19.6%	10.5%	24.1%	25.7%	26.1%	25.4%	24.5%	24.6%	25.8%	25.1%
	20	20	24	21	62	61	27	51	39	26
PAT margin %	6.3%	6.5%	6.7%	5.9%	12.5%	12.8%	4.9%	8.3%	6.1%	3.8%
EPS (₹)	—	—	5.6	4.9	14.2	13.8	5.7	10.6	8	5.3
EPS adjusted (₹)	4.6	4.7	5.6	4.9	14.3	12.7	5.7	0	8	5.3
	—	—	0%	0%	21.1%	21.8%	53.1%	28.4%	37.5%	56.3%
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	43	43	43	43	43	48	48	48	48	48
Reserves	62	101	125	146	202	378	391	443	470	482
Minority interest	—	—	—	—	—	—	—	0	—	—
	75	82	87	78	64	72	75	99	148	153
	88	89	97	104	130	112	135	153	178	225
Total equity & liabilities	268	315	352	371	439	611	650	743	844	908
	101	104	113	111	112	151	165	182	208	346
CWIP	3	7	17	22	37	28	56	78	99	2
Investments	0	0	0	0	0	0	0	0	0	0
	164	204	223	238	290	433	429	484	536	560
Total assets	268	315	352	371	439	611	650	743	844	908

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	41.9%	41.6%	38.6%	43.2%	34.9%	34.6%	35.7%	35.6%
EBITDA margin %	12.9%	13%	16.6%	18.3%	9.4%	12.1%	11.6%	9.1%
EBIT margin %	10.5%	10.3%	14.6%	16%	7.1%	10%	9.1%	6.5%
PAT margin %	6.7%	5.9%	12.5%	12.8%	4.9%	8.3%	6.1%	3.8%
Working capital
Receivable days	88	94	89	97	108	126	125	141
Inventory days	129	154	121	202	133	126	153	137
Payable days	90	2	104	84	89	103	108	131
NWC days	127	246	106	215	152	149	170	146
Leverage
Current ratio	1.54	1.59	1.72	2.74	2.26	2.08	2.02	1.51
Debt to EBITDA	1.87	1.67	0.79	0.83	1.45	1.33	2.03	2.46
Debt to equity	0.51	0.41	0.26	0.17	0.17	0.2	0.29	0.29
Interest coverage	4.5	4.2	14.4	17	6.9	8.9	6.6	4.3
Asset turnover	1.02	0.97	1.12	0.78	0.85	0.83	0.75	0.75
Return ratios
Return on assets %	6.8%	5.7%	14%	10%	4.2%	6.9%	4.6%	2.8%
Return on capital employed %	20.5%	16.8%	35.1%	23.5%	9%	15.3%	11%	7.8%
Return on equity %	14.3%	11.1%	25.1%	14.3%	6.2%	10.4%	7.4%	4.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	44.49%	44.49%	44.49%	44.49%	44.49%	44.46%	44.42%	44.42%	44.42%	44.42%	44.42%	44.42%
	0.39%	0.48%	0.84%	0.68%	1.32%	0.86%	1.12%	0.76%	0.6%	0.36%	0.57%	0.51%
DII	0.35%	0.14%	1.2%	0.14%	0.22%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	54.77%	54.89%	53.47%	54.69%	53.97%	54.68%	54.46%	54.82%	54.98%	55.22%	55.01%	55.07%
No. of shareholders	—	—	—	—	—	—	—	—	62,222	60,886	58,639	56,925

Promoter holding down 0.07 percentage points since Sep 2023.

105 deals · 15 Mar 2023 – 17 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
17 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Sell	2,57,185	₹265.59	₹6.83 Cr
17 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Buy	2,50,015	₹265.88	₹6.65 Cr
16 Sept 2026	ALPHAGREP SECURITIES PRIVATE LIMITED	Bulk	NSE	Buy	8,82,407	₹263.72	₹23.27 Cr
16 Sept 2026	ALPHAGREP SECURITIES PRIVATE LIMITED	Bulk	NSE	Sell	8,82,407	₹263.91	₹23.29 Cr
16 Sept 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	6,74,213	₹265.76	₹17.92 Cr
16 Sept 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	6,74,213	₹265.54	₹17.90 Cr
16 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	6,00,758	₹262.86	₹15.79 Cr
16 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	5,97,857	₹262.89	₹15.72 Cr
16 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Sell	5,73,173	₹261.62	₹15.00 Cr
16 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Buy	5,62,128	₹260.92	₹14.67 Cr

1–10 of 105

1 / 11

Mr. Surendra SomaniExecutive Director-Chairperson-MD
Mr. Namrata Varun SomaniNon-Executive - Non Independent Director
Basant K SoniChief Financial Officer
Mrs. Mamta Ashok BiyaniNon-Executive - Independent Director
Mr. Narayan Tulsiram AtalNon-Executive - Independent Director
Mr. Varun Surendra SomaniNon-Executive - Non Independent Director
Mr. Chandresh Gunvant GandhiNon-Executive - Independent Director
Sunil SodhaniCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	742	0.02	0.04%	0.002%	+1

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sarvamangal Mercantile Company Ltd1 Oct 2026 · Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Price Movement22 Sept 2026 · General
The Exchange has sought clarification from Kopran Ltd on September 21, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....21 Sept 2026 · Clarification

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

7

Final dividend11 Aug 2026 · ex-date₹3
Final dividend4 Sept 2025 · ex-date₹3
Final dividend2 Sept 2024 · ex-date₹3
Dividend dividend7 Sept 2023 · ex-date₹3
Final dividend4 Aug 2022 · ex-date₹3
Final dividend5 Aug 2021 · ex-date₹1.5
Interim dividend5 Nov 2020 · ex-date₹1.5

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

55 announcementsExport CSV

1 Oct 2026, 8:46 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

22 Sept 2026, 2:17 pmCompany Update

Announcement Under Regulation 30 (LODR) For Price Movement

General PDF

21 Sept 2026, 5:07 pmCompany Update

Clarification sought from Kopran Ltd

Clarification

16 Sept 2026, 4:11 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of ESOP / ESPS PDF

8 Sept 2026, 3:02 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

1 Sept 2026, 12:42 pmCompany Update

Clarification For Increase In Scrip Volume

General PDF

1 Sept 2026, 12:32 pmCompany Update

Clarification sought from Kopran Ltd

Clarification

18 Aug 2026, 4:52 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

Date	Category	Subject	Filing
1 Oct 2026, 8:46 am	Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	PDF
22 Sept 2026, 2:17 pm	Company Update General	Announcement Under Regulation 30 (LODR) For Price Movement

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	41.9%	41.6%	38.6%	43.2%	34.9%	34.6%	35.7%	35.6%
EBITDA margin %	12.9%	13%	16.6%	18.3%	9.4%	12.1%	11.6%	9.1%
EBIT margin %	10.5%	10.3%	14.6%	16%	7.1%	10%	9.1%	6.5%
PAT margin %	6.7%	5.9%	12.5%	12.8%	4.9%	8.3%	6.1%	3.8%
Working capital
Receivable days	88	94	89	97	108	126	125	141
Inventory days	129	154	121	202	133	126	153	137
Payable days	90	2	104	84	89	103	108	131
NWC days	127	246	106	215	152	149	170	146
Leverage
Current ratio	1.54	1.59	1.72	2.74	2.26	2.08	2.02	1.51
Debt to EBITDA	1.87	1.67	0.79	0.83	1.45	1.33	2.03	2.46
Debt to equity	0.51	0.41	0.26	0.17	0.17	0.2	0.29	0.29
Interest coverage	4.5	4.2	14.4	17	6.9	8.9	6.6	4.3
Asset turnover	1.02	0.97	1.12	0.78	0.85	0.83	0.75	0.75
Return ratios
Return on assets %	6.8%	5.7%	14%	10%	4.2%	6.9%	4.6%	2.8%
Return on capital employed %	20.5%	16.8%	35.1%	23.5%	9%	15.3%	11%	7.8%
Return on equity %	14.3%	11.1%	25.1%	14.3%	6.2%	10.4%	7.4%	4.9%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	16	26	25	31	60	-34	34	43	42	67
	-18	-11	-25	-13	-25	-84	-13	-44	-56	-65
	2	-15	-1	-18	-35	123	-20	1	26	-21
Net cash flow	-0	-0	-0	0	0	5	2	1	11	-19
Free cash flow	1	26	25	18	36	-73	-21	-7	-13	8
CFO / Operating profit %	44.1%	84.8%	54.9%	66.4%	73.4%	-38.4%	65.7%	58.1%	57.4%	107.8%

Kopran Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

7

1

Announcements

Not in the F&O segment

7

1

Announcements

Annual reports

Credit ratings

Compounded sales growth

Compounded profit growth

Return on equity

Kopran Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Dividends7

Board meetings1

Announcements

Not in the F&O segment

Dividends7

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

7

1

7

1